Evolving strategies for dose optimization of linezolid for treatment of tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 12, 2016, Pages S48-S51

  Nuermberger, E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Linezolid; Multidrug resistant tuberculosis; Oxazolidinone; Pharmacody namics; Sutezolid

Indexed keywords

LINEZOLID; MITOCHONDRIAL PROTEIN; TUBERCULOSTATIC AGENT;

ARTICLE; DOSE RESPONSE; DRUG CONCENTRATION; DRUG EXPOSURE; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIDE EFFECT; TUBERCULOSIS; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; MULTIDRUG RESISTANT TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LINEZOLID; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85014672979     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0113     Document Type: Article

References (27)

1. Williams K N, Stover C K, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009; 53: 1314-1319.
2. Drusano G L, Neely M, Van Guilder M, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLOS ONE 2014; 9: e101311.
3. Coleman M T, Chen RY, Lee M, et al. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 2014; 6: 265ra167.
4. Dietze R, Hadad D J, McGee B, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008: 178: 1180-1185.
5. Lee M, Lee J, Carroll M W, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
6. Lee M, Cho S N, Barry C E, Song T, Kim Y, Jeong I. Linezolid for XDR-TB - final study outcomes. N Engl J Med 2015; 373: 290-291.
7. Xu H B, Jiang R H, Li L, Xiao H P. Linezolid in the treatment of MDR-TB: a retrospective clinical study. Int J Tuberc Lung Dis 2012; 16: 358-363.
8. Cox H, Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2012; 16: 447-454.
9. Drusano G L, Ambrose P G, Bhavnani S M, Bertino J S, Nafziger A N, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007; 45: 753-760.
10. Bhavnani S M, Ambrose P G, Hammel J P, Rubino C M, Drusano G L. Evaluation of daptomycin exposure and efficacy and safety endpoints to support risk-versus-benefit considerations. Antimicrob Agents Chemother 2015; 60: 1600-1607.
11. th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Cape Town, South Africa, 2-6 December 2015. Session N. 00121. Symposium 45: Finding better treatments sooner: innovations in clinical trials for new regimens beyond 2015.
12. Brown A N, Drusano G L, Adams J R, et al. Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy. MBio 2015; 6: e01741-15.
13. Zhu T, Friedrich S O, Diacon, Wallis R S. Population pharmacokinetic/pharmacodynamic analysis of the bactericidal activities of sutezolid (PNU-100480) and its major metabolite against intracellular Mycobacterium tuberculosis in ex vivo whole-blood cultures of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2014; 58: 3306-3311.
14. Louie A, VanScoy B D, Heine H S, et al. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrob Agents Chemother 2012; 56: 513-517.
15. Louie A, Heine H S, Kim K, et al. Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother 2008; 52: 2486-2496.
16. Deshpande D, Srivastava S, Pasipanodya P, et al. Linezolid for babies and toddlers with disseminated tuberculosis: first steps. Clin Infect Dis 2016 (in press).
17. Rayner C R, Forrest A, Meagher A K, Birmingham M C, Schentag J J. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-1423.
18. Balasubramanian V, Solapure S, Shandil R, et al. Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis. Antimicrob Agents Chemother 2014; 58: 4185-4190.
19. Koh W J, Kwon O J, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
20. Alffenaar J W, van AR, Harmelink I M, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.
21. McGee B, Dietze R, Hadad D J, et al. Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2009; 53: 3981-3984.
22. Song T, Lee M, Jeon H S, et al. Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis. EBio Med 2015; 2: 1627-1633.
23. Cattaneo D, Orlando G, Cordier L. Linezolid for extensively drug-resistant tuberculosis. N Engl J Med 2013; 368: 291.
24. Matsumoto K, Shigemi A, Takeshita A, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents 2014; 44: 242-247.
25. Chang K C, Yew W W, Cheung S W, et al. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis? Antimicrob Agents Chemother 2013; 57: 3445-3449.
26. Tasneen R, Betoudji F, Tyagi S, et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 60: 270-277.
27. Boak L M, Rayner C R, GraysonM L, et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 2014; 58: 2334-2343.